It is concluded that a dose range from background dose to several cGy may be separated into two parts: a) first--the interval of small doses limited from above by D* which is determined from (1 g (D*/Doc)) < -0.51 g (n/2)), where Dse is an average dose of a single event, n--quantity of irradiated cells; in this interval only one track intersects a sensitive volume; b) second--the interval of low doses, in which in average one track intersects the volume and which is ranged from top D* to bottom Dse. Because events in this region qualitatively are similar to background events, cells in the dose range b) may be adapted to the influence of radiation. The first stage of the adaptive response of cells is associated with chromosome loci (centromere) movement in a cell nucleus and as we suggest the latter is the fundamental mechanism for repairing DSB DNA and switching of gene transcription. Because the movement of chromosome loci both in the resting cells under the adapting doses and in the normal dividing cells is much the same (but the latter lose their function characteristic for differentiated resting cells), it could be assumed that the resting cells under the adapting doses also lose their functional parameters. Under chronic exposure to low doses this functional changes can be principal for discussion on the influence of low doses on health.
Download full-text PDF |
Source |
---|
J Radiol Prot
January 2025
The University of Manchester, Manchester, M13 9PL, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND.
Epidemiological studies of nuclear industry workers are of substantial importance to understanding the risk of cancer consequent to low-level exposure to radiation, and these studies should provide vital evidence for the construction of the international system of radiological protection. Recent studies involve large numbers of workers and include health outcomes for workers who accumulated moderate (and even high) doses over prolonged periods while employed during the earlier years of the nuclear industry. The interpretation of the findings of these recent studies has proved to be disappointingly difficult.
View Article and Find Full Text PDFEndocr Connect
January 2025
A Munir, Diabetes and Endocrinology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom of Great Britain and Northern Ireland.
Omissions or delays in desmopressin can result in serious patient harm in patients with Arginine-Vasopressin Deficiency (AVP-D), formally known as Cranial Diabetes Insipidus (CDI). Desmopressin administration practice in hospitals has not been thoroughly investigated previously. This study evaluated desmopressin prescription and administration practice at a large tertiary centre.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Pediatrics, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh.
Background: Juvenile Idiopathic arthritis (JIA) is one of the most common chronic diseases in children. It still remains a challenge to treat refractory poly-articular course JIA patients, especially in Bangladesh, where patients from low socio-economic backgrounds are unable to manage biological agents. Tofacitinib is one of the alternative options to biological agents, which can be taken orally and is cost effective.
View Article and Find Full Text PDFJNCI Cancer Spectr
January 2025
Exact Sciences Corporation, Madison, WI, United States.
Background: Multi-cancer early detection (MCED) tests may expand cancer screening. Characterizing diagnostic resolution approaches following positive MCED tests is critical. Two trials employed distinct resolution approaches: a molecular signal to predict tissue of origin (TOO) and an imaging-based diagnostic strategy.
View Article and Find Full Text PDFPaediatr Anaesth
January 2025
Department of Anaesthesiology, Adolphe de Rothschild Foundation Hospital, Paris, France.
Background: Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare life-threatening inborn error of neurotransmitter biosynthesis. It is characterized by deficient biosynthesis of neurotransmitters dopamine and serotonin, leading to catecholamines deficiency and sympathetic deprivation, while the parasympathetic system remains functional. Since 2012, gene therapy has led to clinical improvements in symptoms and motor function with a severe phenotype.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!